Recent Company News

• 03:56 AM ET Nov 09, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (55 total)

• 01:11 AM ET Nov 09, 2026
  

  UCB and Biogen announce further data characterizing the clinical profile of dapirolizumab pegol (DZP); associated with greater treatment response rates versus placebo in SLE using novel treatment response measure (€290.90, 0.00)

• 01:08 AM ET Nov 09, 2026
  

  Biogen announces further data on dapirolizumab pegol at ACR Convergence 2026 ($248.35, 0.00)

• 01:03 AM ET Nov 09, 2026
  

  UCB announces bimekizumab-bkzx builds on superior joint responses versus SKYRIZI at Week 16, with clinical improvements sustained through Week 24 (€290.90, 0.00)

• 04:34 AM ET Oct 22, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:10 AM ET Oct 22, 2026
  

  UCB raises FY adj. EBITDA growth guidance to low- to mid-forties range from mid-teens to low-twenties range at constant exchange rates (€213.00, 0.00)

• 04:56 PM ET Oct 13, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 01:10 AM ET Oct 16, 2026
  

  UCB gets FDA approval for first self-administered once-daily, autoinjector administration option for the treatment of gMG in adult patients who are AChR antibody positive with ZILBRYSQ (€206.00, 0.00)

• 04:20 AM ET Oct 14, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (86 total)